Treatment of NSCLC lines with the JAK2 inhibitor ruxolitinib inhibits anchorage independent growth and slows xenograft tumor formation, suggesting that selected patients with NSCLC may benefit from treatment with JAK2 inhibitors in addition to TKI. This evidence concerns the gene JAK2 and non-small cell lung carcinoma.